Shares of Biocon Ltd rose to a day high of Rs 325.50 on 26 October after the drugmaker won rights to sell Yesintek in nine more countries.

In a filing to the exchanges, the Bengaluru-based company disclosed a licence agreement with Janssen Sciences Ireland. It takes effect immediately.

A biosimilar is a lower-cost version of an existing branded biologic medicine, and the original here is Stelara.

Biocon can now sell its copy in Australia, Brazil, China, Hong Kong, Mexico, Israel, New Zealand, Kazakhstan and South Korea, though each launch still needs local regulatory approval.

Yesintek is approved to treat Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, all conditions linked to an overactive immune system.

In simple terms, the body’s own defences attack healthy tissue in these illnesses.

Stelara pulled in $6.08 billion in worldwide sales in 2025, a figure Biocon quoted in its filing.

The company said the added markets will let it offer patients an affordable treatment option.

Entry dates for the US, Europe, the UK, Canada and Japan were already locked in under earlier Janssen deals. Nine more markets now join that list.

Separately, on 14 October, Biocon settled its patent disputes with Genentech over Pebrilzo, a biosimilar to the breast cancer drug Perjeta, securing launch dates in the EU and UK in the first quarter of 2027 and the third quarter of 2028 in the United States.

Launches remain subject to regulatory approval in each region.

At 9:40 am, the stock’s trading at Rs 321.95 on NSE, down 0.48% from the previous close, after opening at Rs 323 and slipping to a low of Rs 321.60.

The stock has dropped 15.75% over the past month and 16.97% so far this year, and it sits close to its 52-week low of Rs 318.40 hit on 23 October.

Feeling overwhelmed by the markets? Let Tradz by EquityPandit be your guide. Our user-friendly app simplifies complex data and provides actionable trading signals. Download the app today and trade with confidence!